Lupin launches Tolvaptan Tablets in US market with 180-day exclusivity
Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity.
Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
a day ago
- Business Standard
Lupin launches Ipratropium Bromide Nasal Solution in US market
Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
Indian pharmaceutical major Lupin on Thursday announced the launch of a new nasal spray — Ipratropium Bromide Nasal Solution — in the United States market. The product is available in two strengths: 0.03 per cent and 0.06 per cent. The company stated that the spray is used to treat runny nose (rhinorrhoea) caused by allergies, the common cold or other non-allergic conditions. It is suitable for both adults and children, depending on the prescribed strength. The product is the generic version of a nasal spray called Atrovent, which is already available in the US market. The spray is considered bioequivalent, meaning it acts in the same way in the body as the reference drug. Lupin has a strong presence in the US and European pharmaceutical markets. As reported by Business Standard in May, the company is targeting a greater share of revenue from its complex generics portfolio in the US and Europe. With a pipeline of over 200 products over the next five years, Lupin expects the revenue share from complex generics to reach 62 per cent by FY30. The contribution from such products is projected at 21 per cent by FY26. Complex generics include high-value products such as inhalers, injectables, transdermal patches and ophthalmic solutions, which typically contain more sophisticated active ingredients and delivery mechanisms. Generic drugs are copies of branded medicines that have gone off-patent. Complex generics differ from simple generics in terms of formulation, technology and margin potential. On Friday, Lupin's shares closed at ₹1,978 on the Bombay Stock Exchange, up ₹22.40 or 1.15 per cent.
Business Standard
a day ago
- Business Standard
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
Lupin has announced the launch of Ipratropium Bromide Nasal Solution (nasal spray) in two strengths in the United States. Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today.
